NDC 49281-590
MenQuadfi
Neisseria Meningitidis Group A Capsular Polysaccharide Tetanus Toxoid Conjugate Antigen, Neisseria Meningitidis Group C Capsular Polysaccharide Tetanus Toxoid Conjugate Antigen, Neisseria Meningitidis Group Y Capsular Polysaccharide Tetanus Toxoid Conjugate Antigen, And Neisseria Meningitidis Group W-135 Capsular Polysaccharide Tetanus Toxoid Conjugate Antigen
MenQuadfi is a Intramuscular Injection, Solution in the Vaccine category. It is labeled and distributed by Sanofi Pasteur Inc.. The primary component is Neisseria Meningitidis Group A Capsular Polysaccharide Tetanus Toxoid Conjugate Antigen; Neisseria Meningitidis Group C Capsular Polysaccharide Tetanus Toxoid Conjugate Antigen; Neisseria Meningitidis Group Y Capsular Polysaccharide Tetanus Toxoid Conjugate Antigen; Neisseria Meningitidis Group W-135 Capsular Polysaccharide Tetanus Toxoid Conjugate Antigen.
| Product ID | 49281-590_47cb6429-8c73-4723-93cb-270071d5eaf1 |
| NDC | 49281-590 |
| Product Type | Vaccine |
| Proprietary Name | MenQuadfi |
| Generic Name | Neisseria Meningitidis Group A Capsular Polysaccharide Tetanus Toxoid Conjugate Antigen, Neisseria Meningitidis Group C Capsular Polysaccharide Tetanus Toxoid Conjugate Antigen, Neisseria Meningitidis Group Y Capsular Polysaccharide Tetanus Toxoid Conjugate Antigen, And Neisseria Meningitidis Group W-135 Capsular Polysaccharide Tetanus Toxoid Conjugate Antigen |
| Dosage Form | Injection, Solution |
| Route of Administration | INTRAMUSCULAR |
| Marketing Start Date | 2020-04-23 |
| Marketing Category | BLA / BLA |
| Application Number | BLA125701 |
| Labeler Name | Sanofi Pasteur Inc. |
| Substance Name | NEISSERIA MENINGITIDIS GROUP A CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN; NEISSERIA MENINGITIDIS GROUP C CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN; NEISSERIA MENINGITIDIS GROUP Y CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN; NEISSERIA MENINGITIDIS GROUP W-135 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN |
| Active Ingredient Strength | 10 ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
Packaging
NDC 49281-590-05
5 VIAL, SINGLE-DOSE in 1 CARTON (49281-590-05) > .5 mL in 1 VIAL, SINGLE-DOSE (49281-590-58)
| Marketing Start Date | 2020-04-23 |
| NDC Exclude Flag | N |
| Sample Package? | N |
NDC SPL Data Element Entries
NDC 49281-590-05 [49281059005]
MenQuadfi INJECTION, SOLUTION
| Marketing Category | BLA |
| Application Number | BLA125701 |
| Product Type | VACCINE |
| Marketing Start Date | 2020-04-23 |
NDC 49281-590-58 [49281059058]
MenQuadfi INJECTION, SOLUTION
| Marketing Category | BLA |
| Application Number | BLA125701 |
| Product Type | VACCINE |
| Marketing Start Date | 2020-04-23 |
Drug Details
Active Ingredients
| Ingredient | Strength |
|---|---|
| NEISSERIA MENINGITIDIS GROUP A CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN | 10 ug/.5mL |
Trademark Results [MenQuadfi]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 MENQUADFI 88053768 not registered Live/Pending |
Sanofi Pasteur Inc. 2018-07-26 |
© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.